• Pharmacyclics Inc., of Sunnyvale, Calif., said the New England Journal of Medicine online published results of a Phase II study evaluating the investigational oral Bruton's tyrosine kinase inhibitor, ibrutinib, in patients with relapsed/refractory mantle cell lymphoma (MCL). The data suggest ibrutinib may be effective and generally well tolerated in patients with relapsed/refractory MCL.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter